Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
Definitive Healthcare Corp. (NASDAQ:DH) reported a change to its board of directors this week, according to a press release statement based on a recent SEC filing. The healthcare data analytics company, currently valued at approximately $600 million, has shown strong momentum with a 5.5% gain over the past week, though InvestingPro analysis suggests the stock is currently trading below its Fair Value.
On Sunday, Jill Larsen resigned from the company’s board of directors and as chair and member of the Human Capital Management and Compensation Committee. The resignation became effective Monday. The company stated that Ms. Larsen’s decision was due to increased responsibilities at her current employer and was not the result of any disagreements with Definitive Healthcare regarding its operations, policies, or practices.
Following Ms. Larsen’s departure, the size of the board was reduced from 10 members to 9 members. The board subsequently appointed Scott Stephenson as a member and chair of the Human Capital Management and Compensation Committee.
Definitive Healthcare Corp. is incorporated in Delaware and its Class A common stock is listed on the Nasdaq Stock Market under the symbol DH. The information in this article is based on a press release statement and a Form 8-K filed with the Securities and Exchange Commission.
In other recent news, Definitive Healthcare reported its first-quarter 2025 financial results, showing revenue of $59.2 million. This figure surpassed both the company’s own guidance and analyst estimates from BTIG and consensus forecasts, which stood at $56.6 million and $56.2 million, respectively. Despite this achievement, the revenue marked a 7% decline from the previous year. The company’s adjusted EBITDA was $14.7 million, exceeding BTIG’s and consensus estimates of $10.5 million and $10.7 million, though it represented a 26.5% decrease from the prior year. Additionally, Definitive Healthcare achieved an adjusted net income of $7 million, or $0.05 per share, which was above the high-end of its guidance. BTIG analysts responded by downgrading the stock from Buy to Neutral, citing concerns over year-over-year declines and ongoing market challenges. These developments highlight the complex financial landscape facing Definitive Healthcare.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.